Our Stories

Our Stories

트위터 링크드

18/03/2020 SAMSUNG BIOEPIS UPDATE ON COVID-19
As the coronavirus (COVID-19) continues to affect many parts of the world, we are committed to ensuring the health and safety of our patients and dedicated colleagues working at Samsung Bioepis.
Supply of Our Medicines

We are committed to ensuring the continued supply of our medicines to patients in need.

To date, we have had no disruptions and based on current inventory levels, we do not anticipate any shortage in the foreseeable future

We are closely collaborating with our manufacturing partners across the world to implement strict prevention and response measures against COVID-19

We have always maintained multi-source strategy to mitigate the risk of supply chain disruptions, and will continue to closely monitor inventory levels to accommodate market dynamics and fluctuations

Health and Safety of Our Colleagues and Community

Since the breakout of COVID-19, we have taken proactive measures to protect the health and well-being of our colleagues, families, and the community, and by extension the patients we serve.

To prevent the spread of COVID-19, we have ongoing disinfection of our facilities across the two campuses in South Korea. We have also implemented strict preventive measures such as health screening, restrictions on large in-person meetings and non-essential business travels, and limitations on external visitors to Samsung Bioepis sites.

more